**CIBMTR SC21-07/BMT CTN 2101**

**Observational Study for BMT/CAR-T Patients Receiving the COVID Vaccine**

|  |  |
| --- | --- |
| **WHY** | There are no data on the efficacy of the COVID-19 vaccines in HCT/CAR-T patients* We do not know if our patients are protected!
* In SOT patients, only 17% had detectable Ab ~3 weeks after the first dose of mRNA vaccine
 |
| **WHO** | Patient must meet the following:* ≤12 months from cell infusion (Auto/Allo/CAR) for any disease
* Signed the CIBMTR Database Consent with valid CRID
	+ Confirm with [\*\*\*]
 |
| **WHEN** | Scheduled/Scheduling to receive the COVID-19 Vaccine in the next 2 – 3 weeks |
| **HOW** | Step 1:* Discuss the study with the patient.
	+ 4 samples obtained at [\*\*\*] (see below for timing)
	+ After 4th sample collected and tested, the Ab results will be returned to provider to discuss results with the patient
* Contact [\*\*\*] for consent

Step 2: * Schedule initial clinic visit (or identify suitable clinic visit already scheduled) for CBC/diff + research labs [and provider visit if allo]

Step 3: * [\*\*\*] will track patients and notify you regarding the timing of subsequent visits (CBC/diff + research labs [and provider visit if allo])
 |

**Timing of Samples**

**Any 2-dose Vaccine** [ex. mRNA vaccine (Pfizer/Moderna)]

|  |  |  |  |
| --- | --- | --- | --- |
| **#1** | **#2** | **#3** | **#4** |
| Any time **1 – 14 days before** the 1st dose of vaccine | **1 – 7 days before** the 2nd dose of vaccine | Any time between **7 to 35 days after** the 2nd dose of vaccine | Any time between **6 and 8 months after** the 1st dose of vaccine |

**Any 1-dose vaccine** [ex. J&J]

|  |  |  |  |
| --- | --- | --- | --- |
| **#1** | **#2** | **#3** | **#4** |
| Any time up to **1 – 14 days before** the 1st dose of vaccine | Any time between **14 days and 35 days after** the vaccine | Any time between **4 and 8 weeks after** sample #2 | Any time between **6 and 8 months after** the 1st dose of vaccine |